Phase 1 Lung Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You have a stored tissue sample available for testing
- You have advanced or spreading breast cancer that is ER-positive and HER2-negative, a type of non-small cell lung cancer, a type of prostate cancer, or a specific type of colorectal cancer, and your cancer has continued to grow after at least one standard treatment (this applies to one part of the trial only)
- You have ER-positive, HER2-negative breast cancer that has continued to grow after at least one hormonal therapy and a specific type of targeted therapy called a CDK4/6 inhibitor (this applies to other parts of the trial)
- If you are a woman with ER-positive, HER2-negative breast cancer who could still become pregnant (or have only had your tubes tied), you must be willing to have your menstrual cycle medically stopped for certain parts of the trial
- If you are a woman who can no longer become pregnant, you must be aged 60 or over, or under 60 with no period for at least 12 months, or have had both ovaries removed
- You are generally well enough to carry out light daily activities (confirm with trial site)
- Your bone marrow, kidneys, and liver are functioning well enough, as shown by blood tests
- Your life expectancy is more than 3 months
- You are able to swallow and keep down tablets or capsules by mouth
- You are able to follow the contraception or barrier method requirements of the trial
Who may not be able to join:
- You have brain tumours that are causing symptoms, or cancer that has spread to the lining around the brain or spinal cord
- You have a primary brain cancer, or have had another type of cancer within the last 2 years (with some exceptions for certain fully treated localised cancers)
- You have a digestive system condition that could affect how your body absorbs the study medication
- You have an active liver or bile duct disease
- You have an active infection (bacterial, fungal, or viral) that is not under control
- You have had a significant heart problem or blood clotting event within the 6 months before joining the trial
- You still have significant side effects from a previous experimental cancer treatment that have not improved sufficiently
- More than 25% of your bone marrow has previously been treated with radiation therapy
- You have a known allergy or sensitivity to the study drug or its ingredients, or to a drug called fulvestrant and its ingredients (for certain parts of the trial only)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Safety and Tolerability of IDE574 in Part 1 A Monotherapy Dose escalation; Safety and Tolerability of IDE574 in Part 1B Monotherapy Dose expansion based on incidence and severity of AEs/SAEs; To evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on the ORR per RECIST version 1.1; To evaluate anti-tumor activity of IDE574 of IDE574 in Part 1B Monotherapy Dose expansion based on DOR per RECIST version 1.1.; Safety and tolerability of IDE574 in combination with Fulvestrant in Part 2A Combination Dose Escalation based on incidence of DLT; Safety and tolera...
Can't join this trial?
Data last synced from ClinicalTrials.gov: 30 June 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.